Aurinia Pharmaceuticals (AUPH) Receivables (2016 - 2026)

Aurinia Pharmaceuticals (AUPH) has 11 years of Receivables data on file, last reported at $49.2 million in Q1 2026.

• Quarterly Receivables rose 21.87% year-over-year to $49.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.2 million (up 21.87% YoY) and the FY2025 annual result came in at $41.5 million, up 13.44% from the prior year.
• Receivables climbed to $49.2 million in Q1 2026, from $41.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $49.2 million in Q1 2026 to a low of $13.5 million in Q4 2022.
• A 5-year average of $30.8 million and a median of $30.7 million in 2025 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables surged 1618.7% — and 2025, when it dropped 15.77%.
• Tracing AUPH's Receivables over 5 years: stood at $13.5 million in 2022, then soared by 78.44% to $24.1 million in 2023, then surged by 51.7% to $36.5 million in 2024, then gained by 13.44% to $41.5 million in 2025, then grew by 18.63% to $49.2 million in 2026.
• The last three Receivables figures came in at $49.2 million (Q1 2026), $41.5 million (Q4 2025), and $30.7 million (Q3 2025), per Business Quant data.